




PHARMACEUTICAL 2023

Propanc Biopharma Inc.
Rank 444 of 446





PHARMACEUTICAL 2023

Propanc Biopharma Inc.
Rank 444 of 446

The relative strengths and weaknesses of Propanc Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Propanc Biopharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 494% points. The greatest weakness of Propanc Biopharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 340% points.

The company's Economic Capital Ratio, given in the ranking table, is -510%, being 554% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	15
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,063
Liabilities, Non-Current	42
Other Assets	65
Other Compr. Net Income	-551
Other Expenses	-27
Other Liabilities	0
Other Net Income	-722
Other Revenues	0
Property and Equipment	2.0
Research and Development	256
Selling, General and Administrative Expense	1,706

Output Variable	Value in 1000 USD
Assets	82
Liabilities	3,105
Expenses	1,936
Revenues	0
Stockholders Equity	-3,024
Net Income	-2,658
Comprehensive Net Income	-2,934
Economic Capital Ratio	-510%